|Slideshows|June 7, 2016

Psychiatry Roundup: Suicide, Overdose, and Self-Harm

A recent study reported that burnout rates in one hospital were over 75%. This story and more in our psychiatry roundup.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

“Porosity”: Connecting 2 Western Cultural Psychiatric Discourses in Tokyo by Way of Naples

ByVincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych, FRSC

October 29th 2025

Social Determinants of Health and Mental Health: Concepts and Practice of Growing Relevance

ByRenato D. Alarcón, MD, MPH,Dilip V. Jeste, MD

October 16th 2025

The Psychiatric Lens on Extraordinary Experiences: Improving Care Without Misdiagnosis

ByMarina Weiler, PhD,Marieta Pehlivanova, PhD,Philip J. Cozzolino, PhD,J. Kim Penberthy, PhD, ABPP

September 29th 2025

Social Psychiatry and Culturally Relevant Psychotherapy at the APA Annual Meeting

ByLeah Kuntz,Vincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych, FRSC

May 28th 2025

After the Wildfires: Reflections on Positive Psychiatry and Posttraumatic Growth

ByDave Baron, DO, MSEd

March 4th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Psychiatry Roundup: Suicide, Overdose, and Self-Harm

Newsletter

Related Content

“Porosity”: Connecting 2 Western Cultural Psychiatric Discourses in Tokyo by Way of Naples

Social Determinants of Health and Mental Health: Concepts and Practice of Growing Relevance

The Psychiatric Lens on Extraordinary Experiences: Improving Care Without Misdiagnosis

Social Psychiatry and Culturally Relevant Psychotherapy at the APA Annual Meeting

After the Wildfires: Reflections on Positive Psychiatry and Posttraumatic Growth

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Vagus Nerve Stimulation in Treatment Resistant Depression: New Lines of Thinking

Glutamatergic Pathways in Major Depressive Disorder: Insights From Juan D. Oms, MD, FAPA

Improving Outcomes in Schizophrenia With Long-Acting Injectables: Insights from the Southern Florida Psychiatry Conference

Pharmacologic Management of Stuttering: What Psychiatrists Need to Know

Novel Therapeutic Targets for Major Depressive Disorder: In Conversation With Ginger Shupe, MD